Smart and innovative strategies with rationally engineered peptide vaccines and/or peptide mimics could establish a new paradigm in cancer immunotherapy.

The trial consisted of four cohorts with increasing doses of peptide vaccines ranging from 0.5 to 3.0 mg. Eligible patients received three inoculations 3 weeks apart. A total of 24 patients (six ...